FDA Grants Priority Review to Praxis’s Relutrigine for Rare Epileptic Encephalopathies
Event summary
- FDA accepted Praxis’s NDA for relutrigine, a treatment for SCN2A and SCN8A developmental and epileptic encephalopathies (DEEs), with a PDUFA target action date of September 27, 2026.
- Relutrigine, a first-in-class small molecule, has received Orphan Drug, Rare Pediatric Disease, and Breakthrough Therapy designations.
- The NDA submission is supported by positive results from the EMBOLD study, which was stopped early for efficacy.
- Relutrigine, if approved, would be the first FDA-approved therapy for SCN2A/8A DEE and eligible for a Pediatric Review Voucher.
The big picture
Praxis’s NDA acceptance for relutrigine marks a critical step in its transition to a commercial-stage company, addressing a significant unmet need in rare epileptic encephalopathies. The FDA’s priority review designation underscores the therapeutic potential of relutrigine, which, if approved, would be the first targeted treatment for SCN2A and SCN8A DEEs. The strategic focus on precision neuroscience positions Praxis to capitalize on the growing demand for genetically targeted therapies in CNS disorders.
What we're watching
- Regulatory Success
- Whether the FDA’s priority review will result in approval by the September 27, 2026, target date.
- Commercialization Readiness
- The pace at which Praxis can prepare for the potential launch of relutrigine, given the upcoming regulatory decision.
- Clinical Pipeline
- The progress of the EMERALD trial, which is investigating relutrigine in broader DEEs and expected to complete by the end of 2026.
Related topics